EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.
James McIlory, MBChB, BMedSci
Advertisement
James McIlroy, MBChB, BMedSci, is founder and CEO of EnteroBiotix.
Articles by James McIlory, MBChB, BMedSci
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
4
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
5